These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21370269)

  • 21. Unawareness of motor phenoconversion in Huntington disease.
    McCusker EA; Gunn DG; Epping EA; Loy CT; Radford K; Griffith J; Mills JA; Long JD; Paulsen JS;
    Neurology; 2013 Sep; 81(13):1141-7. PubMed ID: 23966256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unified Huntington's disease rating scale: a follow up.
    Siesling S; van Vugt JP; Zwinderman KA; Kieburtz K; Roos RA
    Mov Disord; 1998 Nov; 13(6):915-9. PubMed ID: 9827615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive domains that predict time to diagnosis in prodromal Huntington disease.
    Harrington DL; Smith MM; Zhang Y; Carlozzi NE; Paulsen JS;
    J Neurol Neurosurg Psychiatry; 2012 Jun; 83(6):612-9. PubMed ID: 22451099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study.
    Biglan KM; Ross CA; Langbehn DR; Aylward EH; Stout JC; Queller S; Carlozzi NE; Duff K; Beglinger LJ; Paulsen JS;
    Mov Disord; 2009 Sep; 24(12):1763-72. PubMed ID: 19562761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebellar abnormalities in Huntington's disease: a role in motor and psychiatric impairment?
    Rees EM; Farmer R; Cole JH; Haider S; Durr A; Landwehrmeyer B; Scahill RI; Tabrizi SJ; Hobbs NZ
    Mov Disord; 2014 Nov; 29(13):1648-54. PubMed ID: 25123926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal assessment of the Unified Huntington's Disease Rating Scale (UHDRS) and UHDRS-For Advanced Patients (UHDRS-FAP) in patients with late stage Huntington's disease.
    Winder JY; Achterberg WP; Gardiner SL; Roos RAC
    Eur J Neurol; 2019 May; 26(5):780-785. PubMed ID: 30576046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.
    Mov Disord; 1996 Mar; 11(2):136-42. PubMed ID: 8684382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of rivastigmine on motor and cognitive impairment in Huntington's disease.
    de Tommaso M; Specchio N; Sciruicchio V; Difruscolo O; Specchio LM
    Mov Disord; 2004 Dec; 19(12):1516-8. PubMed ID: 15390067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pilot study using nabilone for symptomatic treatment in Huntington's disease.
    Curtis A; Mitchell I; Patel S; Ives N; Rickards H
    Mov Disord; 2009 Nov; 24(15):2254-9. PubMed ID: 19845035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Female Sexual Dysfunction in Presymptomatic Mutation Carriers and Patients with Huntington's Disease.
    Kolenc M; Kobal J; Podnar S
    J Huntingtons Dis; 2017; 6(2):105-113. PubMed ID: 28482643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Informativeness of Early Huntington Disease Signs about Gene Status.
    Oster E; Eberly SW; Dorsey ER; Kayson-Rubin E; Oakes D; Shoulson I
    J Huntingtons Dis; 2015; 4(3):271-7. PubMed ID: 26444024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suicidal ideation and suicidal behavior according to the C-SSRS in a European cohort of Huntington's disease gene expansion carriers.
    van Duijn E; Vrijmoeth EM; Giltay EJ; Bernhard Landwehrmeyer G;
    J Affect Disord; 2018 Mar; 228():194-204. PubMed ID: 29253686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Earliest functional declines in Huntington disease.
    Beglinger LJ; O'Rourke JJ; Wang C; Langbehn DR; Duff K; Paulsen JS;
    Psychiatry Res; 2010 Jul; 178(2):414-8. PubMed ID: 20471695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Motor outcome measures in Huntington disease clinical trials.
    Reilmann R; Schubert R
    Handb Clin Neurol; 2017; 144():209-225. PubMed ID: 28947119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.
    Russell DS; Barret O; Jennings DL; Friedman JH; Tamagnan GD; Thomae D; Alagille D; Morley TJ; Papin C; Papapetropoulos S; Waterhouse RN; Seibyl JP; Marek KL
    JAMA Neurol; 2014 Dec; 71(12):1520-8. PubMed ID: 25322077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimising mobility outcome measures in Huntington's disease.
    Busse M; Quinn L; Khalil H; McEwan K
    J Huntingtons Dis; 2014; 3(2):175-88. PubMed ID: 25062860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hand tapping: a simple, reproducible, objective marker of motor dysfunction in Huntington's disease.
    Michell AW; Goodman AO; Silva AH; Lazic SE; Morton AJ; Barker RA
    J Neurol; 2008 Aug; 255(8):1145-52. PubMed ID: 18465109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Premanifest Huntington's disease: Examination of oculomotor abnormalities in clinical practice.
    Winder JY; Roos RAC
    PLoS One; 2018; 13(3):e0193866. PubMed ID: 29494703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-motor symptoms in Huntington's disease: a comparative study with Parkinson's disease.
    Aldaz T; Nigro P; Sánchez-Gómez A; Painous C; Planellas L; Santacruz P; Cámara A; Compta Y; Valldeoriola F; Martí MJ; Muñoz E
    J Neurol; 2019 Jun; 266(6):1340-1350. PubMed ID: 30834978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study.
    Paulsen JS; Long JD; Ross CA; Harrington DL; Erwin CJ; Williams JK; Westervelt HJ; Johnson HJ; Aylward EH; Zhang Y; Bockholt HJ; Barker RA;
    Lancet Neurol; 2014 Dec; 13(12):1193-201. PubMed ID: 25453459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.